Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands, colon, endometrium, uterus, bladder, bones, blood, etc. Zanidatamab is an anti-cancer drug that acts on cells with alterations in the HER2 gene. It is used in Europe to treat people with bile duct cancer. However, in various clinical trials, zanidatamab has shown promising activity in a few patients with different cancers that have a HER2 gene alteration. This treatmen

Trial Details

NCT ID
NCT07192068
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Zanidatamab
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Marseille, France|43.29695,5.38107
  • Vandœuvre-lès-Nancy, France|48.66115,6.17114
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Histologically or cytologically confirmed endometrial, colorectal, head \& neck, non-small cell lung cancer (NSCLC), or sarcoma
  • Patient with progressive, unresectable and/or advanced or metastatic disease harboring a locally performed, centrally reviewed HER2-overexpressing …
  • Age ≥ 18 years at inclusion
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →